Bristol Myers Squibb Co $49.92

down -0.12


21/8/2014 03:17 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has underperformed the S&P 500 by 0%

Partner Headlines

  1. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  2. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  3. Drugmaker AstraZeneca Returns To Growth

    IBD
  4. The Stocks Already in Correction Mode

    FoxBusiness
  5. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  6. Bristol-Myers surprises Street

    IBD
  7. Thursday Morning Earnings Reports

    Benzinga
  8. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  9. Earnings Scheduled For July 24, 2014

    Benzinga
  10. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  11. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  12. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  13. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  14. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  15. Bristol seeks cancer drug nod

    IBD
  16. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  17. Japan approves BMY regimen

    IBD
  18. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  19. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  20. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  21. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  22. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  23. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  24. Benzinga's Top Downgrades

    Benzinga
  25. Ex-Dividends For July 1, 2014

    Benzinga
  26. Pfizer and others get EU nods

    IBD
  27. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  28. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  29. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  30. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  31. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  32. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  33. BRISTOL-MYERS SQUIBB

    IBD
  34. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  35. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  36. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  37. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  38. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  39. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  40. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  41. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  42. Bristol, Merck Q1 sales soft

    IBD
  43. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  44. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

    Benzinga
  45. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  46. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  47. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone Payments ...

    Benzinga
  48. Earnings Scheduled For April 29, 2014

    Benzinga
  49. Stocks To Watch For April 29, 2014

    Benzinga
  50. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
Trading Center